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Sex Differences in the
Drug-Eluting Stent Era
Do They Still Exist?*
Cindy L. Grines, MD, Theodore Schreiber, MD
Detroit, Michigan
Over the past several years, there has been increasing focus
on obtaining sex-specific data in the cardiovascular area.
This is particularly important, given that cardiovascular
disease remains the greatest cause of death in women, and
unlike men, the mortality rates do not seem to be declining in
recent years (1). Many have attributed this finding to difficul-
ies in recognizing symptoms; delay in diagnosis; under-use of
ecommended diagnostic tests and therapies in women (2–4);
as well as anatomic, physiological, and genetic differences.
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Several studies have confirmed that women who present
with coronary disease are older and have more comorbidities,
including diabetes, hypertension, and heart failure, compared
with men (3–7). Moreover, women with acute coronary
syndromes or myocardial infarction have an increased risk of
mortality that is not consistently eliminated after adjustments
for comorbidities (3–9). Women who undergo coronary artery
bypass grafting (CABG) are less likely to receive a mammary
graft and have more incomplete revascularization, greater
bleeding, and mortality, compared with men (10).
The good news is that outcomes after coronary revascu-
larization are improving. A single-center study noted better
30-day and 1-year outcomes among women undergoing
percutaneous coronary interventions (PCI) after the year
2000 (11). A national registry reported that sex was no
longer predictive of major adverse cardiac events in the era
of stenting (12). Drug-eluting stents (DES) seem to be
equally effective at reducing restenosis and improving out-
comes in both men and women (13–19). In fact, second-
generation DES might be particularly well-suited for the
small tortuous coronary arteries found in some women,
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In this issue of JACC: Cardiovascular Interventions, Ste-
fanini et al. (20) described their pooled data on more than
5,000 patients enrolled in 3 prospective randomized DES
trials. Their study is unique in that patients were not highly
selected, use of second- and third-generation DES was
unrestricted, and 2-year follow-up was available. Although
women experienced a higher mortality at 30 days, by 2 years,
adjusted mortality was similar (odds ratio: 0.99, 95% con-
fidence interval: 0.63 to 1.56, p  0.97), as was target vessel
revascularization. Among the patients who underwent
protocol-driven angiographic follow-up, late loss and reste-
nosis rates were similar among men and women (despite
smaller vessels and more diabetes in women).
Results of the Stefanini et al. study (20) and others
(13–19) suggest that DES have leveled the playing field
between men and women undergoing PCI. Many studies
have shown that acute angiographic success, late restenosis,
and clinical outcomes are now similar between men and
women, despite advanced age and more comorbidities in the
latter. These results are likely due to improvements in
catheters and more flexible stent designs. Conversely, other
investigators continue to report higher mortality (21) and
target vessel revascularization (16,18,20) in women.
Moreover, the risk of femoral access site complications
and bleeding remains significantly increased in women.
Given the greater understanding of the risk of vascular
complications in women, many physicians are using radial
access or bivalirudin as the antithrombotic of choice in
women. To further elucidate the risk/benefit ratio of these
strategies, the Safe-PCI (Study of Access Site for Enhance-
ment of PCI for Women) trial will randomize 3,000 women
to radial versus femoral approach (22).
So, have we answered most of the questions with regard
to cardiac differences between men and women? Not by a
long shot. There seems to be fundamental biological differ-
ences in vascular structure, function, and atherosclerotic
plaque between men and women. The mechanism of acute
myocardial infarction is different between the sexes, with
women having a higher prevalence of Takotsubo infarc-
tions, subendocardial myocardial infarctions, spontaneous
dissection, and plaque erosion, compared with men (23–26).
Vasospastic disorders, such as pulmonary hypertension,
Reynaud’s phenomena, migraines, and coronary microvas-
cular disease, occur more commonly in women (27–30).
Clearly there are hormonal influences contributing to peri-
partum cardiomyopathy and spontaneous coronary dissec-
tion. Moreover, complications during pregnancy, such as
gestational diabetes or preeclampsia are risk factors for
future cardiac events in women.
Thus, we are only at our infancy in our understanding of
sex differences in cardiovascular disease. Although it is an
incredible success that both women and men can now
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312undergo PCI with similar benefits, elucidation of differences
in the prevalence, mechanism, manifestation, and treatment of
cardiovascular disease will require more sex-specific investiga-
tions.
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